AstraZeneca Buy Back , PTV News: Mar 02, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AstraZeneca Buy Back , PTV News: Mar 02, 2010
Released on: March 02, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Company
British company exercises option to buy out Merck & Co's interest in some of its products.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
AstraZeneca
AstraZeneca plc is a British-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries (ICI), as three divisions that were spun off from ICI on 1 June 1993. It is a public company and is listed on the London Stock Exchange, the New York Stock Exchange and the OMX exchange.
Merck & Co.
Merck & Co., Inc., also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The headquarters of the company is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. It was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and set up as an independent company. It is currently one of the seven largest pharmaceutical companies in the world both by market capitalisation and revenue.

Merck's products cover a broad range of areas, including heart and respiratory health, infectious diseases, sun care and women’s health. And Merck focuses its research on conditions that affect millions of people around the world – diseases like Alzheimer’s, diabetes and cancer – while building strengths in new areas like biologics.